Last reviewed · How we verify
AZD6244 Dosing Period 1
MEK inhibitor
MEK inhibitor Used for Non-small cell lung cancer.
At a glance
| Generic name | AZD6244 Dosing Period 1 |
|---|---|
| Also known as | AZD6244 |
| Sponsor | AstraZeneca |
| Drug class | MEK inhibitor |
| Target | MEK1 and MEK2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AZD6244 is a potent and selective inhibitor of MEK1 and MEK2, enzymes that are key regulators of the MAPK/ERK signaling pathway.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD6244 Dosing Period 1 CI brief — competitive landscape report
- AZD6244 Dosing Period 1 updates RSS · CI watch RSS
- AstraZeneca portfolio CI